Bimokalner | 2243284-19-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Bimokalner
• 英文别名: (1S,2S,4R)-N-[[3-(pentafluoro-λ6-sulfanyl)phenyl]methyl]bicyclo[2.2.1]heptane-2-carboxamide
• CAS: 2243284-19-5
• 化学式: C₁₅H₁₈F₅NOS
• 分子量: 355.4
• InChiKey: KTTBVFVRXDRSSP-OSMZGAPFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  30.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• CYCLIC AMIDES, ACTEAMIDES AND UREAS USEFUL AS POTASSIUM CHANNEL OPENERS
  申请人：Acousia Therapeutics GmbH

  公开号：EP3366683A1

  公开（公告）日：2018-08-29

  The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein - n = 0 or 1 , - RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, alkylcycloalkyl groups, aryl groups, arylalkyl groups and arylcycloalkyl groups, which optionally contain heteroatoms, and - RR is a substituent selected from the group consisting of unsubstituted or substituted aryl groups, alkylaryl groups, and arylalkyl groups, which optionally contain heteroatoms, - or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.

  本发明公开了可用作钾通道开放剂，特别是用作 Kv7.4 钾通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 式中 - n = 0 或 1 、 - RL 是选自未取代或取代的环烷基、烷基环烷基、芳基、芳烷基和芳基环烷基（可选含有杂原子）的取代基，以及 - RR 是一个取代基，选自由未取代或取代的芳基、烷芳基和芳烷基组成的组，其中可选含有杂原子、 - 或其立体异构体、同系物、原药或盐，最好是药学上可接受的盐。
• PENTACYCLOTHIENYL AND INDANYL UREA DERIVATIVES AS POTASSIUM CHANNEL OPENERS
  申请人：Acousia Therapeutics GmbH

  公开号：EP3567034A1

  公开（公告）日：2019-11-13

  The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein - n = 0 or 1, - RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and - RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, - or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.

  本发明公开了可用作钾通道开放剂，特别是用作 Kv7.4 钾通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 其中 - n = 0 或 1、 - RL 是一个取代基，选自由未取代或取代的环烷基（尤其是双环烷基）、未取代或取代的苯基、未取代或取代的噻吩基或环戊二烯基和未取代或取代的茚基组成的组，这些基团可选择含有杂原子，以及 - RR 是一个取代基，选自由未取代或取代的苯基或未取代或取代的苄基（可选含有杂原子）组成的组、 - 或其立体异构体、同系物、原药或盐，最好是药学上可接受的盐。
• Compounds useful as potassium channel openers
  申请人：ACOUSIA THERAPEUTICS GMBH

  公开号：US11034665B2

  公开（公告）日：2021-06-15

  The present invention discloses novel compounds which are useful as potassium channel openers, in particular as openers of the Kv7.4 potassium channel. The novel compounds are compounds according to formula I, wherein n=0 or 1, RL is a substituent selected from the group consisting of unsubstituted or substituted cycloalkyl groups, in particular bicycloalkyl groups, unsubstituted or substituted phenyl groups, unsubstituted or substituted thienyl groups or cyclopentathienyl groups, and unsubstituted or substituted indanyl groups, which optionally contain heteroatoms, and RR is a substituent selected from the group consisting of unsubstituted or substituted phenyl groups or unsubstituted or substituted benzyl groups, which optionally contain heteroatoms, or a stereoisomer, a tautomer, a prodrug or a salt, preferably pharmaceutically acceptable salt thereof.

  本发明公开了可用作钾通道开放剂，特别是用作 Kv7.4 钾通道开放剂的新型化合物。这些新型化合物是符合式 I 的化合物、 式中 n=0 或 1、 RL 是一个取代基，选自由未取代或取代的环烷基（尤其是双环烷基）、未取代或取代的苯基、未取代或取代的噻吩基或环戊二烯基，以及未取代或取代的茚基组成的组，这些基团可选择含有杂原子，以及 RR 是一个取代基，选自由未取代或取代的苯基或未取代或取代的苄基（可选含有杂原子）组成的组、 或其立体异构体、同系物、原药或盐，最好是药学上可接受的盐。
• NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS
  申请人：Acousia Therapeutics GmbH

  公开号：EP3484863A2

  公开（公告）日：2019-05-22
• CYCLIC AMIDES AS POTASSIUM CHANNEL OPENERS
  申请人：Acousia Therapeutics GmbH

  公开号：EP3484863B1

  公开（公告）日：2020-06-17